Home>Topics>Stocks>Roche Holding AG ADR

Roche Holding AG ADR RHHBY

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. CareDx settles royalty dispute with Roche

      Headlines

      Wed, 17 Sep 2014

      CareDx ( CDNA -4.6% ) settles its arbitration case with Roche ( OTCQX: RHHBY -0.3% ) over unpaid PCR-related royalties on AlloMap revenue. CareDx agrees to pay Roche $2,827,220 to settle past

    2. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

      Headlines

      Tue, 16 Sep 2014

      Sanofi* SNY 4 Wide 56.43 0.88 3.3 Medium 5 3 Roche* RHHBY 3 Wide 36.7 1.05 3 Low 5 - Eli Lilly LLY 3 Wide 65.27 ..... for Pfizer PFE, General Electric GE, Sanofi SNY, and Roche RHHBY , but the yields remain fairly comparable, even though the

    3. Roche initiates GA drug Phase 3 trial

      Headlines

      Mon, 15 Sep 2014

      Roche ( OTCQX: RHHBY ) commences a Phase 3 clinical trial to evaluate the safety and efficacy of lampalizumab for the treatment of patients with geographic

    4. Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor

      Headlines

      Thu, 11 Sep 2014

      By Dr. Paul Nunzio DeSantis, Pharm.D : Abbvie's (NYSE: ABBV )'s proactive and strategic efforts throughout 2014 are undoubtedly welcome measures by shareholders who are increasingly weary of ABBV's dependence on Humira as patent expiration arrives in 2016. We specifically support their £53.80 bid

    5. Is Roche At Risk Of Losing Its Way?

      Headlines

      Tue, 9 Sep 2014

      By Stephen Simpson, CFA : By just about any reasonable standard, Roche (OTCQX: RHHBY ) is an exceptional pharmaceutical and diagnostics company. Through internal efforts and acquisitions large and small (particularly

    6. Achillion - An Options Strategy For A Potential Acquisition

      Headlines

      Mon, 8 Sep 2014

      By Small Pharma Analyst : A few months ago, Merck (NYSE: MRK ) surprised investors by acquiring Idenix (NASDAQ: IDIX ) for $3.85 billion, a 239% premium to its closing share price of the prior day. This was an unexpected acquisition, since most thought the HCV field was set, with the major players

    7. EC approves RoActemra label expansion for the treatment of early RA

      Headlines

      Mon, 8 Sep 2014

      The European Commission approves Roche's ( OTCQX: RHHBY ) RoActemra ( tocilizumab ) for the treatment of patients with severe, active and progressive rheumatoid arthritis (RA) who

    8. Infiniti and Roche ink supply agreements

      Headlines

      Wed, 3 Sep 2014

      The two firms sign a master clinical supply agreement whereby Roche ( OTCQX: RHHBY +0.7% ) will supply Gazyva ( obinutuzumab ) to Infiniti Pharmaceuticals ( INFI +46.2% ) for use in planned clinical studies

    9. Roche launches new molecular testing systems

      Headlines

      Tue, 2 Sep 2014

      Roche ( OTCQX: RHHBY -0.3% ) debuts the molecular testing systems cobas 6800/8800 for blood and plasma donor screening in markets accepting the

    10. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      firms. That has culminated in deals such as GlaxoSmithKline's GSK acquisition in 2012 of Human Genome Sciences and Roche's RHHBY recent announcement of its plans to acquire InterMune ITMN. Given Big Pharma's flush balance sheets, we expect more biotechs

    « Prev12345Next »
    Content Partners